Rebif 44 microgrammi/0.5ml soluzione iniettabile in cartuccia ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-004450-21-IT (EUCTR) | 07/02/2014 | 12/12/2013 | study to evaluate whether the administration of Rebif ® 44 three times a week in the morning can reduce the severity of flu-like symptoms compared to administration in the evening, in patients with relapsing multiple sclerosis not yet treated. | Multicenter, open-label, 12 weeks,phaseIV pRospectivE randomized study aimed at evaLuating whether sc IFN beta 1a(Rebif®) administered In the morning may affEct the severity of Flu-like syndromeand patient perceived invisible symptoms in subjects with relapsing multiple sclerosis - RELIEF | relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Rebif 44 microgrammi/0.5ml soluzione iniettabile in cartuccia Product Name: Rebif® | Merck Serono S.p.A. | NULL | Not Recruiting | Female: yes Male: yes | 218 | Phase 4 | Italy |